Vivek Ramaswamy buys Strive Inc (ASST) stock worth $1.25 million
NEW YORK - Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with a market capitalization of $93.79 billion and currently considered undervalued according to InvestingPro analysis, will present new data reinforcing the efficacy and safety profile of Camzyos (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) at the American Heart Association’s Scientific Sessions 2025, taking place November 7-10 in New Orleans.
The presentations will include analyses from a long-term extension study spanning nearly four years and real-world evidence from the largest safety cohort to date. Key data includes an evaluation of Camzyos’ effects on cardiac structure and biomarker levels based on duration of diagnosis, and a healthcare resource utilization analysis examining hospitalization and emergency room visit rates among U.S. patients with symptomatic oHCM.
"Camzyos has reset the baseline for treating adults with symptomatic oHCM, allowing physicians and patients to move beyond symptom management to a treatment that has consistently demonstrated an ability to significantly reduce obstruction, impact cardiac structure, and improve symptoms," said Cristian Massacesi, MD, executive vice president, Chief Medical Officer at Bristol Myers Squibb, according to the press release.
Currently approved in more than 50 countries, Camzyos has been prescribed to tens of thousands of patients worldwide. In the U.S. alone, more than 4,000 healthcare professionals have prescribed the medication to over 20,000 patients. Bristol Myers Squibb continues to demonstrate strong financial fundamentals with a healthy 16% free cash flow yield and a 5.38% dividend yield, having maintained dividend payments for an impressive 55 consecutive years.
The company will also present data on milvexian, an investigational oral Factor XIa inhibitor being developed in collaboration with Johnson & Johnson.
Camzyos is a selective, reversible cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
In other recent news, Bristol-Myers Squibb reported quarterly earnings that surpassed analyst expectations, leading to a 7% increase in its stock. Despite the positive earnings report, Bernstein SocGen Group maintained its Market Perform rating on the company, with a price target of $58.00, suggesting that the stock’s rise may have been influenced by previous investor pessimism. Meanwhile, BioNTech experienced a significant increase in third-quarter revenue, which exceeded expectations, although the company reported a loss where analysts had anticipated a profit. BioNTech’s revenue reached €1.52 billion, well above the analyst consensus of €1.01 billion, largely due to a $1.5 billion payment from its collaboration with Bristol-Myers Squibb. This collaboration also led BioNTech to raise its full-year revenue guidance. Despite the earnings miss, BioNTech’s shares rose by 2.9% following these announcements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.